FDA approves Reblozyl (luspatercept-aamt) for treatment of beta thalassemia in adults
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The u.SFoodDrug(http://Administration (
FDA(http://) recently approved Reblozyl (luspatercept-aamt) for the treatment of beta thalassemia in adultsAbout Reblozyl
Reblozyl is an innovative red blood cell maturant (EMA) that promotes the maturation of late red blood cells in animal modelsReblozyl's treatment of beta thalassemia indications is based on data from the key PHASE III BELIEVE studyThis is a randomized, double-blind, placebo-controlled, multicenter study carried out in patients with blood transfusion-dependent beta thalassemiaThe study reached the primary and all key secondary endpointsThe results showed that patients in the luspatercept treatment group had significantly less blood transfusion burden than the placebo groupIn terms of safety
the most common therapeutic adverse reactions include headache, bone pain, joint pain, fatigue, cough, abdominal pain, diarrhea, and dizziness Patients may develop high blood pressure when using Reblozyl It is recommended to monitor the patient's blood pressure during treatment and, if necessary, to begin antihypertensive treatment Patients treated with Reblozyl should monitor thrombosis The FDA recommends that health professionals medical (http:// ) to inform women of childbearing age that effective contraception should be used during treatment with Reblozyl Pregnant or lactating women should not take Reblozyl as it may cause harm to a developing fetus or newborn baby
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
